{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tislelizumab&page=2", "query": { "intervention": "tislelizumab", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 66, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tislelizumab&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tislelizumab&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-01T16:01:17.145Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02407990", "title": "Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "BGB-A317", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 451, "start_date": "2015-06-02", "completion_date": "2020-08-12", "has_results": true, "last_update_posted_date": "2021-11-17", "last_synced_at": "2026-10-01T16:01:17.145Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02407990" }, { "nct_id": "NCT06427941", "title": "A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Hepatocellular Carcinoma", "Local Advanced Hepatocellular Carcinoma", "Alpha-fetoprotein (AFP)-Producing Gastric Cancer", "Extragonadal Yolk Sac Tumors", "Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer" ], "interventions": [ { "name": "BGB-B2033", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 630, "start_date": "2024-07-23", "completion_date": "2028-10-31", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-01T16:01:17.145Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Duarte, California + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Zion", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06427941" }, { "nct_id": "NCT03777657", "title": "Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric, or Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 997, "start_date": "2018-12-13", "completion_date": "2024-08-27", "has_results": true, "last_update_posted_date": "2025-02-14", "last_synced_at": "2026-10-01T16:01:17.145Z", "location_count": 6, "location_summary": "Sacramento, California • Newnan, Georgia • Columbus, Ohio + 3 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Newnan", "state": "Georgia" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "West Reading", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03777657" }, { "nct_id": "NCT04215978", "title": "Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Non Small Cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Nasopharyngeal Carcinoma (NPC)" ], "interventions": [ { "name": "BGB-A445", "type": "DRUG" }, { "name": "tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 204, "start_date": "2020-01-30", "completion_date": "2025-01-24", "has_results": false, "last_update_posted_date": "2025-10-03", "last_synced_at": "2026-10-01T16:01:17.145Z", "location_count": 3, "location_summary": "Los Angeles, California • San Diego, California • Pittsburgh, Pennsylvania", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04215978" }, { "nct_id": "NCT04318080", "title": "Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Classical Hodgkin Lymphoma" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2020-08-20", "completion_date": "2024-08-29", "has_results": true, "last_update_posted_date": "2025-09-24", "last_synced_at": "2026-10-01T16:01:17.145Z", "location_count": 3, "location_summary": "Detroit, Michigan • Knoxville, Tennessee • Salt Lake City, Utah", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Knoxville", "state": "Tennessee" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04318080" }, { "nct_id": "NCT06422520", "title": "A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "BGB-C354", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2024-07-08", "completion_date": "2026-05-15", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-10-01T16:01:17.145Z", "location_count": 5, "location_summary": "Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 2 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06422520" }, { "nct_id": "NCT05207709", "title": "Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Ribociclib + Letrozole OR Fulvestrant", "type": "DRUG" }, { "name": "Palbociclib + Letrozole OR Fulvestrant", "type": "DRUG" }, { "name": "Paclitaxel +/- Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SOLTI Breast Cancer Research Group", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2022-03-28", "completion_date": "2026-03-26", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-01T16:01:17.145Z", "location_count": 26, "location_summary": "Clearwater, Florida • Coral Gables, Florida • Hollywood, Florida + 22 more", "locations": [ { "city": "Clearwater", "state": "Florida" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05207709" }, { "nct_id": "NCT07377045", "title": "Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Adenocarcinoma Metastatic" ], "interventions": [ { "name": "OMTX705", "type": "DRUG" }, { "name": "Nab-paclitaxel + Gemcitabine", "type": "DRUG" }, { "name": "Tislelizumab (i.v. 200mg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncomatryx Biopharma S.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2025-10-28", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-10-01T16:01:17.145Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07377045" }, { "nct_id": "NCT05768932", "title": "BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "TNBC - Triple-Negative Breast Cancer", "Gastric Cancer", "Leukemia Acute Myeloid Leukemia (AML)" ], "interventions": [ { "name": "BAL0891", "type": "DRUG" }, { "name": "Tislelizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Paclitaxel", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "SillaJen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2022-12-14", "completion_date": "2026-12-24", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-10-01T16:01:17.145Z", "location_count": 11, "location_summary": "New Haven, Connecticut • Coral Gables, Florida • Atlanta, Georgia + 6 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05768932" }, { "nct_id": "NCT07290985", "title": "AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastroesophageal Adenocarcinoma" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Zanidatamab", "type": "DRUG" }, { "name": "Zolbetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "American Association for Cancer Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 242, "start_date": "2026-07-20", "completion_date": "2028-12-01", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-10-01T16:01:17.145Z", "location_count": 2, "location_summary": "Los Angeles, California • New Haven, Connecticut", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT07290985" } ] }